Citadel Advisors
PXMD

Citadel Advisors’s PaxMedica, Inc. Common Stock PXMD Stock Holding History

Citadel Advisors’s Portfolio PXMD Stock Details PXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-27,973
Closed -$21.2K – 15867
2023
Q4 		$21.2K Buy
+27,973
New +$64.8K ﹤0.01% 12577
2023
Q3 		– Sell
-4,058
Closed -$54.2K – 15441
2023
Q2 		$54.2K Buy
+4,058
New +$99.5K ﹤0.01% 11702

Other funds holding PXMD

SFA
Souders Financial Advisors Cincinnati, Ohio $876M AUM 14.39% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return

Citadel Advisors's PXMD Position: Q1 2024 in Review

Citadel Advisors sold out of PaxMedica, Inc. Common Stock (PXMD) in Q1 2024, closing a stake of 27,973 shares — an estimated $21.2K sold.

Citadel Advisors first reported a position in PXMD in Q2 2023 and held it in 2 quarters. The position peaked at $54.2K in Q2 2023. 8 funds tracked by Wall St. Rank hold PXMD as of Q1 2024.

  • Citadel Advisors reported no remaining PaxMedica, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 27,973 PaxMedica, Inc. Common Stock shares in Q1 2024, an estimated $21.2K.
  • Citadel Advisors first reported a position in PaxMedica, Inc. Common Stock in Q2 2023 and held it in 2 quarters.
  • Citadel Advisors's PaxMedica, Inc. Common Stock position peaked at $54.2K in Q2 2023.
  • 8 funds tracked by Wall St. Rank held PaxMedica, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.